KT-413 |CAS 2655656-99-6|DC Chemicals

Cas No.:	2655656-99-6
Chemical Name:	IRAK degrader-1
Synonyms:	2655656-99-6;compound A [WO2022027058A1];SCHEMBL23696494;CS-0694448;N-[2-[4-[[6-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethyl]-2-azaspiro[3.3]heptan-2-yl]methyl]cyclohexyl]-5-(2-hydroxypropan-2-yl)-1,3-benzothiazol-6-yl]-6-(trifluoromethyl)pyridine-2-carboxamide;GTPL11904;SCHEMBL23696217;HY-153368;IRAK degrader-1;SCHEMBL23539538;N-[2-[trans-4-[[6-[2-[[2-(2,6-Dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethyl]-2-azaspiro[3.3]hept-2-yl]methyl]cyclohexyl]-5-(1-hydroxy-1-methylethyl)-6-benzothiazolyl]-6-(trifluoromethyl)-2-pyridinecarboxamide
SMILES:	S1C2C=C(C(C(C)(C)O)=CC=2N=C1C1CCC(CC1)CN1CC2(C1)CC(CCNC1=CC=CC3C(N(C4C(NC(CC4)=O)=O)C(C1=3)=O)=O)C2)NC(C1C=CC=C(C(F)(F)F)N=1)=O
Formula:	C₄₅H₄₈F₃N₇O₆S
M.Wt:	871.966139793396
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC67514	Abd110	Abd110 (compound 42i) is a PROTAC molecule derived from lenalidomide that specifically targets ATR kinase for degradation. This compound demonstrates remarkable selectivity, effectively reducing both ATR and phospho-ATR levels while sparing related DNA damage response kinases ATM and DNA-PKcs.
DC67513	MS8847	MS8847 represents a novel PROTAC molecule that selectively targets EZH2 for degradation by recruiting the VHL E3 ubiquitin ligase complex. This compound mediates potent, proteasome-dependent elimination of EZH2, demonstrating significant anti-proliferative effects against both AML and TNBC cell lines.
DC67512	PROTAC BRD4 Degrader-21	PROTAC BRD4 Degrader-21 (Compound 74) is a potent and selective degrader of BRD4, demonstrating robust tumor growth suppression in mouse xenograft models. Its efficacy supports its potential as a promising candidate for anticancer drug development.
DC67462	YJ1206	YJ1206 is an orally bioavailable PROTAC compound that selectively degrades CDK12 and CDK13, demonstrating potent activity (IC50 = 12.55 nM) in VCaP cells. It induces DNA damage, triggers apoptosis, and drives tumor regression in treatment-resistant prostate cancer PDX models, highlighting its therapeutic potential.
DC67177	BTK-IN-29	BTK-IN-29 (compound 14) is an inhibitor of Btk.
DC67098	cis-AGB1	Cis-AGB1 is a negative control for AGB1 . Exhibits no significant VHL binding affinity.
DC60681	SD-436	SD-436 is a highly potent and selective STAT3 degrader with DC50 of 0.1 nM in human PBMCs and displays >10,000-fold degradation selectivity for STAT3 over other STAT proteins.
DC67029	KT-413	KT-413 (example I-3) is a potent IRAK degrader.
DC65811	KT-253	KT-253 is a potent small molecule that stabilizes p53 while simultaneously acting as a PROTAC to degrade MDM2 (DC50 = 0.4 nM). It demonstrates strong antiproliferative effects in RS4;11 leukemia cells (IC50 = 0.3 nM), inducing G2/M cell cycle arrest and apoptosis. In vivo studies confirm its antitumor activity in mouse models.
DC65810	KT-333	KT-333 is a first-in-class molecular glue that induces selective degradation of STAT3 via the ubiquitin-proteasome system by simultaneously engaging STAT3 and the VHL E3 ligase. This novel mechanism enables potent STAT3 depletion with minimal off-target effects, demonstrating strong anti-tumor activity in hematologic malignancies.